Literature DB >> 1671471

Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure.

M Storck1, W H Hartl, E Zimmerer, D Inthorn.   

Abstract

In a comparison of spontaneous continuous arteriovenous haemofiltration (CAVH) and pump-driven haemofiltration (PDHF) for acute renal failure after surgery, 116 patients admitted to a surgical intensive care unit were assigned CAVH (48) or PDHF (68). The method of assignment was that a patient was treated by PDHF if he or she was the only patient requiring treatment at that time (only one pump was available); any other patient coming to the unit would be treated by CAVH. The groups were slightly unbalanced because there were fewer simultaneous cases than expected. The main endpoints were survival rate, control of uraemia, and additional application of haemodialysis. There were no differences between the patient groups in age, duration of treatment, severity of illness, serum creatinine concentration at the start of treatment, or cause of acute renal failure. Both treatments adequately controlled uraemia and fluid overload. However, the survival rate was significantly higher with PDHF than with CAVH (6 [12.5%] vs 20 [29.4%]; p less than 0.05). The daily ultrafiltrate volume was significantly higher with PDHF than with CAVH (15.7 [95% confidence interval 13.6-17.8] vs 7.0 [6.6-7.4] l/day; p less than 0.05). The volume of ultrafiltrate in patients with ischaemic or sepsis-induced acute renal failure was correlated with the survival rate. This finding suggests that the better survival rate in the PDHF group was due to faster elimination of toxic mediators (of molecular weight 800-1000 daltons) through the filter membrane by high-volume haemofiltration.

Entities:  

Mesh:

Year:  1991        PMID: 1671471     DOI: 10.1016/0140-6736(91)93393-n

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

Review 1.  The pulmonary physician and critical care. 3. Pharmacotherapy in lung injury.

Authors:  M Messent; M J Griffiths
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Septic shock and multiple organ failure: treatment with haemofiltration?

Authors:  M Storck; W H Hartl; D Inthorn
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Acute renal failure in paediatric patients: the role of continuous haemofiltration.

Authors:  S Fanconi; E P Leumann
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Acute renal failure in the ICU in the 1990s--"anything goes"?

Authors:  P Nair; D Bihari
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

5.  Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs.

Authors:  E F Yekebas; H Treede; W T Knoefel; C Bloechle; E Fink; J R Izbicki
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

Review 6.  Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense?

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-02       Impact factor: 17.440

Review 7.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

8.  Continuous veno-venous haemofiltration following cardio-pulmonary bypass. Indications and outcome in 35 patients.

Authors:  S V Baudouin; J Wiggins; B F Keogh; C J Morgan; T W Evans
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

9.  Pump-assisted hemofiltration in infants with acute renal failure.

Authors:  E N Ellis; D Pearson; L Robinson; C W Belsha; T G Wells; P L Berry
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

10.  Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study.

Authors:  R Bellomo; H Teede; N Boyce
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.